Inclusion Criteria:

- Adult patients defined by age ≥ 18 years

- Histologically confirmed Renal cell carcinoma (RCC)

- Locally advanced or metastatic RCC. Locally advanced RCC: defined as a stage . .
T3/T4 disease, not amenable to curative surgery or radiation therapy, with
involvement of renal vein/vena cava/peripelvic and perirenal fat/adrenal gland, or
invasion beyond Gerota's fascia (Moch et al., 2009). Metastatic RCC: equivalent to
Stage IV RCC, according to American Joint Committee on Cancer (AJCC) staging

- Eastern Collaborative Oncology Group (ECOG) Performance Status of ≤ 2. An ECOG of ≤ 1
for the patient with failure of >= 2 prior target therapies is acceptable

- Documented RCC disease with measurable or non-measurable lesion on imaging by RECIST
v1.1 (Response Evaluation Criteria in Solid Tumors) criteria

- Documented treatment failure of at least 1 prior target therapy (sorafenib, sunitinib
pazopanib or other VEGF TKI, bevacizumab, temsirolimus, everolimus or other mTOR
inhibitor) for advanced or metastatic RCC. If treatment-naïve, . patients with poor
prognosis features according to Memorial Sloan-Kettering Cancer Centre (MSKCC) risk
criteria are acceptable

- Any acute or chronic adverse effects of prior therapy have resolved to determined by CTCAE v4.0 criteria

- Laboratory values at screening:

- Absolute neutrophil count ≥ 1,500 /mm3;

- Platelets ≥ 100,000 /mm3;

- Hemoglobin ≥ 9.0 g/dL;

- Total bilirubin ≤ 1.5 times the upper limit of normal;

- AST (SGOT) ≤ 2.5 times the upper limit of normal;

- ALT (SGPT) ≤ 2.5 times the upper limit of normal;

- Serum creatinine ≤ 2 times the upper limit of normal;

Exclusion Criteria:

- Pregnancy or lactation. Women of childbearing potential must have a negative serum
pregnancy test within 7 days prior to enrolment. Male and female patients of
childbearing potential must agree to use appropriate birth control (barrier methods
with spermicides, oral or parenteral contraceptives and/or intrauterine devices)
during the entire duration of the study, or the patient must be surgically sterile
(with documentation in the patient's medical records)

- Receipt of any chemotherapy for RCC

- Had cardiac angioplasty or stenting event, myocardial infarction or unstable angina
within 3 months of study entry

- Persistent QTc >450 ms for males, or >470 ms for females, according to Fridericia's
correction

- Patients with Grade 3 or greater hyponatremia at screening

- History of Class III or IV congestive heart failure according to New York Heart
Association (NYHA) classification

- History of another malignancy, except for non-basal-cell carcinoma of skin or
carcinoma-in-situ of the uterine cervix, and not disease free ≥5 years

- History or presence of central nervous system (CNS) metastasis or leptomeningeal
tumors as documented by CT or MRI scan, analysis of cerebrospinal fluid or
neurological exam

- History of human immunodeficiency virus infection

- Presence of active, uncontrolled infection

- Radiotherapy received within 4 weeks prior to baseline

- Use of any investigational agents within 4 weeks of baseline

- Major surgery within 4 weeks prior to baseline

- Receipt of radiotherapy to >25 % of bone marrow

- Concomitant treatment with, or anticipated use of, pharmaceutical or herbal agents
which are potent inhibitors or inducers of cytochrome P450 enzymes (Appendix D1),
unless approved by the Sponsor

- Uncontrolled intercurrent illness that would jeopardize patient safety, or interfere
with the objectives of the protocol, or limit patient compliance with study
requirements, as determined by the Investigator